Year: 2022
Type: article
Abstract: 177Lu-PSMA-617 radioligand therapy is a novel treatment for end-stage prostate cancer, which could also be applied to patients with hormone-sensitive prostate cancer with high expression levels of prostate-specific membrane antigen (PSMA). In this perspective, we review the recent results of toxicity, radiation doses, and treatment effect of 177Lu-PSMA in patients with low volume metastatic hormone-sensitive prostate cancer. Moreover, we present long-term follow-up data, such as toxicity and time without androgen deprivation therapy (ADT), of the patients who participated in this trial. Overall, 177Lu-PSMA appeared to be a feasible and safe treatment modality in this setting, as well as in long-term follow-up. We observed that men with a prostate-specific antigen (PSA) response of more than 50% seemed to especially benefit from this therapy by postponing ADT and thus preserving the quality of life.
Source: Frontiers in Nuclear Medicine
Authors: Bastiaan M. Privé, Constantijn H. J. Muselaers, Inge M. van Oort, Marcel J. R. Janssen, Steffie M. B. Peters, Willemijn A. M. van Gemert, Maike J. M. Uijen, Melline M. G. Schilham, J. P. Michiel Sedelaar, Harm Westdorp, Niven Mehra, Martin Gotthardt, Jelle O. Barentsz, Winald R. Gerritsen, J. Alfred Witjes, James Nagarajah
Language: English
Subfield: Radiology, Nuclear Medicine and Imaging
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $1,900
Funder: Prostate Cancer Foundation
OpenAlex ID: W4225408370